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Abstract
Objective:  Urinary  tract  infection  (UTI)  caused  by  resistant  strains  of  bacteria  is  increasingly
prevalent  in  children.  The  aim  of  this  study  was  to  investigate  the  clinical  characteristics  and
risk factors  for  UTI  caused  by  community-acquired  extended-spectrum  -lactamase  (CA-ESBL)-
producing  bacteria  in  infants.
Methods:  This  was  a  retrospective  study  performed  over  5  years  in  a  single  Korean  center.
Hospitalized  infants  with  febrile  UTI  were  enrolled  and  divided  into  two  groups  (CA-ESBL  vs.
CA non-ESBL  UTI).  The  yearly  prevalence  was  calculated.  Baseline  characteristics  and  clinical
course such  as  fever  duration,  laboratory  and  radiological  ﬁndings  were  compared  between  the
two groups.  Risk  factors  associated  with  the  CA-ESBL  UTI  were  investigated.
Results: Among  the  enrolled  infants  (n  =  185),  31  (17%)  had  CA-ESBL  UTI.  The  yearly  prevalence
of ESBL  of  CA-ESBL  UTI  increased  during  the  study  (0%  in  2010,  22.2%  in  2015).  Infants  with
CA-ESBL UTI  had  a  longer  duration  of  fever  after  initiating  antibiotics  (2.0  ±  1.1  vs.  1.5  ±  0.6
days, p  =  0.020).  Cortical  defects  on  renal  scan  and  early  treatment  failure  were  more  frequent
in CA-ESBL  (64.5  vs.  42.2%,  p  =  0.023;  22.6  vs.  4.5%,  p  =  0.001).  A  logistic  regression  analysis
revealed that  urinary  tract  abnormalities  and  previous  UTI  were  independent  risk  factors  for
CA-EBSL  UTI  (odds  ratio,  2.7;  p  =  0.025;  10.3;  p  =  0.022).
Conclusion:  The  incidence  of  UTI  caused  by  ESBL-producing  bacteria  has  increased  in  Korean
infants.  Recognition  of  the  clinical  course  and  risk  factors  for  ESLB-producing  UTI  may  help  to
determine  appropriate  guidelines  for  its  management.
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Infecc¸ão do  trato
urinário;
Resistência
antimicrobiana;
-Lactamase;
Fatores  de  risco;
Neonato
Infecc¸ão  do  trato  urinário  causada  por  bactérias  produtoras  de  -lactamases  de
espectro  ampliado  adquiridas  na  comunidade  em  neonatos
Resumo
Objetivo:  A  infecc¸ão  do  trato  urinário  (ITU)  causada  por  cepas  de  bactérias  resistentes  está
cada vez  mais  prevalente  em  crianc¸as.  O  objetivo  deste  estudo  foi  investigar  as  características
clínicas e  os  fatores  de  risco  de  ITU  causada  por  bactérias  produtoras  de  -lactamases  de
espectro  ampliado  adquiridas  na  comunidade  (ESBL  CA)  em  neonatos.
Métodos:  Este  foi  um  estudo  retrospectivo  realizado  por  mais  de  5  anos  em  um  único  centro
coreano.  Neonatos  internados  com  ITU  febril  foram  inscritos  e  divididos  em  dois  grupos  (ITU
por ESBL  CA  em  comparac¸ão  a  não  ESBL  CA).  A  prevalência  anual  foi  calculada.  As  caracterís-
ticas básicas  e  o  curso  clínico,  como  durac¸ão  da  febre  e  achados  laboratoriais  e  radiológicos,
foram comparados  entre  os  dois  grupos.  Os  fatores  de  risco  associados  à  ITU  por  ESBL  CA  foram
investigados.
Resultados:  Entre  os  neonatos  inscritos  (n  =  185),  31  (17%)  apresentaram  ITU  por  ESBL  CA.  A
prevalência  anual  de  ESBL  em  ITU  por  ESBL  CA  aumentou  durante  o  estudo  (0%  em  2010,  22,2%
em 2015).  Os  neonatos  com  ITU  por  ESBL  CA  apresentaram  maior  durac¸ão  de  febre  após  o  início
dos antibióticos  (2,0  ±  1,1  em  comparac¸ão  a  1,5  ±  0,6  dias,  p  =  0,020).  Os  defeitos  corticais
no exame  renal  e  a  falha  precoce  no  tratamento  foram  mais  frequentes  em  ESBL  CA  (64,5
em comparac¸ão  a  42,2%,  p  =  0,023;  22,6  em  comparac¸ão  a  4,5%,  p  =  0,001).  Uma  análise  de
regressão logística  revelou  que  as  anomalias  do  trato  urinário  e  a  ITU  anterior  eram  fatores  de
risco independentes  de  ITU  por  ESBL  CA  (razão  de  chance:  2,7;  p  =  0,025;  10,3;  p  =  0,022).
Conclusão:  A  incidência  de  ITU  causada  por  bactérias  produtoras  de  ESBL  aumentou  em
neonatos coreanos.  O  reconhecimento  do  curso  clínico  e  dos  fatores  de  risco  de  ITU  por  ESBL
poderá ajudar  a  determinar  as  diretrizes  adequadas  de  manejo.
© 2016  Publicado  por  Elsevier  Editora  Ltda.  em  nome  de  Sociedade  Brasileira  de  Pediatria.  Este
e´ um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY-NC-ND  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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risk  factors  for  ESBL  production  were  age,  gender,  urinentroduction
rinary  tract  infection  (UTI)  is  a  common  cause  of
acterial  infections  among  infants  and  young  children
ith  fever  without  a  source.  In  general,  initial  antibi-
tic  therapy  for  UTI  is  empirically  supported  until  the
ulture  and  sensitivity  results  are  available.  However,
ue  to  the  frequent  use  of  antibiotics,  resistant  strains
re  emerging.  The  resistance  of  Gram-negative  bacte-
ia  is  usually  due  to  plasmid-mediated  enzymes  called
xtended-spectrum  -lactamases  (ESBLs).1 These  are  fre-
uently  produced  by  Escherichia  coli  and  Klebsiella  species,
hich  are  the  most  common  UTI-causing  pathogens.2
SBL-producing  bacteria  were  ﬁrst  reported  in  the  1983,3
nd  are  now  widespread  worldwide.4 ESBLs  confer  not
nly  resistance  to  -lactam  antibiotics  but,  oftentimes,
ross-resistance  to  other  antibiotics  such  as  aminogly-
osides,  trimethoprim-sulfamethoxazole  (TMP-SMX),  and
uinolones.5
Infections  caused  by  these  bacteria  are  thought  to  occur
ainly  in  hospitals  and  nursing  homes.6 More  recently,  ESBL-
roducing  bacteria  have  started  to  disseminate  within  the
ider  community;  indeed,  in  many  countries,  the  incidence
f  community-onset  infections  has  increased.7--10 Whereas
everal  studies  have  analyzed  risk  factors  for  UTI  caused
y  ESBL-producing  bacteria  in  adults7,10 and  children,8,9
nly  limited  data  are  available  on  community-acquired  (CA)
TIs  caused  by  ESBL-producing  bacteria  in  infants.  The  aim
f  this  study,  therefore,  was  to  investigate  the  clinical
m
h
nharacteristics  and  risk  factors  for  CA  UTI  caused  by  ESBL-
roducing  bacteria  in  infants.
ethods
tudy  design  and  patient  selection
his  retrospective  study  was  conducted  at  single  center  in
orea  between  January  2010  and  June  2015.  The  criteria
or  enrollment  were  as  follows:  (1)  febrile  UTI  caused  by
.  coli  and  Klebsiella  spp.;  (2)  hospitalized  patients;  (3)
ge  under  12  months.  Patients  who  had  been  hospitalized
ithin  the  past  week  and  those  with  urine  cultures  obtained
ore  than  48  h  after  admission  were  excluded.  UTI  was
eﬁned  as  abnormal  urinalysis  results  and  a positive  urine
ulture  (≥5  ×  104 colony  forming  units/mL)  according  to  the
merican  Academy  of  Pediatrics  guidelines.11 Early  treat-
ent  failure  was  deﬁned  as  fever  persisting  for  more  than
hree  days  despite  antibiotic  treatment.  Bacteremic  UTI  was
eﬁned  as  clinical  symptoms  of  UTI  with  the  same  bacteria
solated  from  urine  and  blood  cultures  at  the  same  time.
he  patient’s  medical  records  were  reviewed  regarding
ata  such  as  age,  gender,  records  of  UTI  episodes  and
rine  culture  results,  past  medical  history,  previous  hospi-
alization,  and  laboratory  and  radiological  ﬁndings.  Possibleicroorganism,  previous  UTI,  use  of  antibiotics,  previous
ospitalization  in  the  previous  three  months,  and  underlying
eurological,  cardiac,  respiratory,  and  renal  diseases.  The
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Figure  1  Incidence  of  CA  ESBL-producing  UTIs  (%  of  total
UTIs).  CA,  community  acquired;  ESBL,  extended-spectrum  -
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CA-ESBL  (+)  UTI  in  infants  
CA-ESBL  and  CA  non-ESBL  groups  were  compared  regarding
the  possible  risk  factors.  The  study  was  approved  by  the
Institutional  Review  Board  of  this  hospital  and  was  in  agree-
ment  with  the  Declaration  of  Helsinki.
Imaging  studies
Renal  abnormalities,  including  vesicoureteral-reﬂux,
hydronephrosis,  and  dysplastic  kidney,  were  investigated.
Renal  ultrasound  (US)  and  technetium-99m  dimercapto-
succinic  acid  (DMSA)  scan  were  performed  to  determine
any  anatomical  abnormalities  and  the  presence  of  acute
pyelonephritis,  respectively.  The  US  results  were  considered
pathological  in  case  of  abnormal  kidney  morphology  and
parenchymal  echogenicity,  any  grade  of  dilatation  of  the
collecting  system  (renal  pelvis,  calyces,  or  distal  ureters),
or  bladder  mucosal  thickening.  An  abnormal  DMSA  result
was  deﬁned  by  the  presence  of  focal  or  diffuse  areas  of
reduced  radionuclide  uptake  without  evidence  of  cortical
loss  or  by  the  presence  of  diffusely  decreased  uptake
in  an  enlarged  kidney.12 DMSA  was  repeated  after  six
months  to  detect  any  renal  cortical  scarring.  Voiding  cys-
tourethrography  was  performed  for  patients  with  abnormal
imaging  results.  The  vesicoureteral  reﬂux  (VUR)  was  graded
according  to  the  International  Reﬂux  Study  Committee
classiﬁcation.13
Identiﬁcation  of  ESBLs
Antimicrobial  susceptibility  testing  was  performed  by  the
disk  diffusion  method  as  recommended  by  the  Clinical
and  Laboratory  Standards  Institute  guidelines.14 ESBL  pro-
duction  was  determined  by  the  double-disk  synergy  test,
also  according  to  the  Clinical  and  Laboratory  Standards
Institute  guidelines.14 A  minimum  5-mm  increase  in  the
zone  tested  in  combination  with  clavulanic  acid  vs.  the
zone  tested  alone  was  accepted  as  an  indication  of  ESBL
production.15
Statistical  analysis
Descriptive  statistics  were  reported  as  mean  with  standard
deviation  or  percentages  where  appropriate.  Continuous
variables  were  analyzed  using  t-tests  for  independent  sam-
ples,  and  categorical  variables  were  analyzed  using  Fisher’s
exact  or  the  chi-squared  test.  Linear  regression  was  used
to  assess  the  trends  of  the  yearly  prevalence  of  CA-ESBL
UTI.  Logistic  regression  was  used  to  determine  the  risk  fac-
tors  for  ESBL-producing  bacteria.  The  results  were  evaluated
with  95%  conﬁdence  intervals.  A  p-value  <  0.05  was  con-
sidered  signiﬁcant.  All  statistical  analyses  were  performed
using  SPSS  version  21.0  (SPSS  Inc.,  IL,  United  States).
Results
A  total  of  185  infants  were  enrolled  and  divided  into
two  groups  (CA-ESBL  vs.  CA  non-ESBL  UTI).  Thirty-one
(16.7%)  of  the  patients  had  UTIs  caused  by  ESBL-producing
bacteria,  while  the  remaining  154  patients  had  non-ESBL-
producing  bacteria  in  their  urine  cultures.  The  proportions  of
U
1
P
ractamase;  UTI,  urinary  tract  infection.  Note:  2015  data  are  for
anuary-June  only;  p  for  trend  <0.001.
SBL-producing  bacteria  causing  UTIs  were  0%  in  2010,  6.9%
n  2011,  13.2%  in  2012,  14.7%  in  2013,  43.3%  in  2014,  and
2.2%  in  2015.  The  yearly  incidence  rates  of  CA-ESBL  UTI
ncreased  during  the  study  period,  and  the  p-value  for  the
rend  was  signiﬁcant  (p  <  0.001;  Fig.  1).
aseline  and  clinical  characteristics
he  CA-EBSL  and  CA  non-ESBL  UTI  groups  consisted  of  31
17%)  and  154  (83%)  patients,  respectively.  The  mean  age
as  higher  in  the  CA-ESBL  UTI  group  than  in  the  non-ESBL
TI  group  (4.2  ±  2.8  vs.  3.1  ±  2.3  months,  p  =  0.018).  E.
oli  was  the  dominant  pathogen  in  both  groups:  the  ESBL-
roduction  proportion  between  E.  coli  and  Klebsiella  spp.
id  not  differ  (Table  1).  No  differences  in  sex  or  laboratory
ndings  were  observed  between  the  two  groups.  Defer-
escence  after  treatment  initiation  was  longer  in  CA-ESBL
TI  than  in  CA  non-ESBL  UTI  (2.0  ±  1.1  vs.  1.5  ±  0.6  days,
 =  0.020;  Table  1).  US  abnormalities  did  not  differ  between
he  groups.  Cortical  defects  on  DMSA  scan  were  more  fre-
uent  in  the  CA-ESBL  than  in  the  CA  non-ESBL  UTI  group  (64.5
s.  43.5%,  p  =  0.023);  however,  presence  of  renal  scars  did
ot  signiﬁcantly  differ  (40.0  vs.  27.3%,  p  =  0.426;  Table  2).
f  the  23  patients  with  CA-ESBL  UTI,  12  (52.2%)  were  diag-
osed  with  VUR,  whose  rate  was  signiﬁcantly  higher  than
hat  in  the  CA-non-ESBL  UTI  group  (p  =  0.027).  Bacteremic
TI  was  observed  in  two  patients  (1.3%)  with  CA  non-ESBL
TI.  Early  treatment  failure  was  more  frequent  in  the  CA-
SBL  UTI  group  than  in  the  CA  non-ESBL  UTI  group  (22.6  vs.
.5%,  p  =  0.001).
ntibiotics  resistance  rates
atients  with  CA-non-ESBL  UTI  showed  a  rate  of  63.6%  of
ntimicrobial  resistance  to  ampicillin.  The  resistance  rates
n  the  CA-ESBL  UTI  group  were  61.3%  for  TMP-SMX,  29.0%  for
iproﬂoxacin,  and  54.8%  for  gentamicin;  in  the  CA  non-ESBL
TI  group,  in  turn,  these  rates  were  30.5%  for  TMP-SMX,
3.0%  for  ciproﬂoxacin,  and  18.2%  for  gentamicin  (Fig.  2).
atients  with  CA-ESBL  UTI  had  a  signiﬁcantly  higher  rate  of
esistance  to  non--lactam  antimicrobial  agents:  19  of  the
ARTICLE IN PRESS+Model
4  Kim  YH  et  al.
Table  1  Baseline  characteristics  of  patients.
ESBL+  (n  =  31)  ESBL−  (n  =  154)  p-Value
Age  (months) 4.2  ±  2.8  3.1  ±  2.3  0.018
Gender
Male 23  120  0.651
Female 8  34
Laboratory  ﬁndings
WBC  (103/mm3)  14.4  ±  7.0  15.5  ±  7.8  0.466
CRP (mg/dL)  4.6  ±  3.6  4.0  ±  3.4  0.436
Urinalysis
Pyuria 28  (90.3%)  152  (98.7%)  0.009
Hematuria 17  (54.8%)  131  (85.1%)  <0.001
Protein 8  (25.8%)  84  (54.5%)  0.004
Nitrite 14  (45.2%)  56  (36.4%)  0.357
Pathogens
E. coli  25  116  0.526
Klebsiella spp. 6  38
Underlying  conditions
Renal  abnormalitiesa 15  (48.4%)  39  (25.3%)  0.010
Anyb 2  (6.5%)  11  (7.1%)  0.891
Previous medical  condition
Use  of  antibiotics 9/30  (30.0%) 22/120  (18.3%) 0.158
Previous UTI  5  (16.1%)  3  (1.9%)  0.001
Recent hospitalization  7  (22.5%)  17  (11.0%)  0.081
-spec
osis, 
3
o
R
R
p
w
i
a
tWBC, white blood count; CRP, C-reactive protein; ESBL, extended
a Renal abnormalities include vesicoureteral-reﬂux, hydronephr
b Cardiac, respiratory, and neurological diseases.
1  ESBL  isolates  (61.3%)  were  resistant  to  at  least  two  groups
f  non--lactam  antibiotic  agents.
isk  factorsegarding  possible  risk  factors,  age,  renal  abnormalities,
revious  UTI,  and  recent  hospitalization  were  associated
ith  CA-ESBL  UTI  (Table  1).  The  logistic  regression  analysis
D
T
C
Table  2  Clinical  course  of  CA-ESBL  UTI  and  CA  non-ESBL  UTI.
ESBL+  (n  =  31)  
Fever  duration  (day)
Total  2.6  ±  1.4  
After initiating  antibiotics  2.0  ±  1.1  
Abnormal USa (n)  21  (67.7%)  
DMSA renal  scan
Cortical  defect  (n)  20  (64.5%)  
Renal scar  (n)  4/10  (40.0%)  
Vesicoureteral-reﬂux  12/23  (52.2%)  
High grade  VUR  (IV,  V)  6/12  (50.0%)  
Treatment failure 7  (9.7%)  
Bacteremic UTI 0  (0%)
ESBL, extended-spectrum -lactamase; UTI, urinary tract infection
vesicoureteral-reﬂux.
a Abnormal US ﬁndings include abnormal parenchymal echogenicity, retrum -lactamase; UTI, urinary tract infection.
and dysplastic kidney.
dentiﬁed  urinary  tract  abnormality  and  previous  UTI  history
s  independent  risk  factors,  which  were  found  to  increase
he  risk  by  2.7-  and  10.3-fold,  respectively  (Table  3).iscussion
he  aim  of  this  study  was  to  highlight  the  emergence  of
A-ESBL  UTIs  in  Korean  infants  and  to  assess  the  clinical
ESBL−  (n  =  154)  p-Value
2.1  ±  1.0  0.085
1.5  ±  0.6  0.020
88  (57.1%)  0.274
65  (42.2%)  0.023
12/44  (27.3%)  0.426
23/83  (27.7%)  0.027
16/23  (69.6%)  0.535
7  (4.5%)  0.001
2  (1.3%)  0.523
; US, ultrasonography; DMSA, dimercaptosuccinic acid; VUR,
nal pelviectasis, hydronephrosis, and bladder mucosa thickening.
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Figure  2  Antibiotic  resistance  of  bacterial  isolates  caus-
ing UTI.  UTI,  urinary  tract  infection;  TMP-SMX,  trimetho-
prim/sulfamethoxazole.  *Multidrug  resistant,  resistant  to  more
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aFisher’s exact  test: 1p  <  0.001; 2p  <  0.001; 3p  =  1.000; 4p  =  0.002;
5p  =  0.005; 6p  <  0.001; 7p  <  0.001; 8p  <  0.001.
characteristics  and  possible  risk  factors  for  CA-ESBL  UTI
in  infants.  An  increasing  incidence  of  multidrug-resistant
bacteria  has  been  reported  not  only  in  hospital-acquired
infections  but  also  CA  infections,  mostly  UTIs.8 Thus,  the
choice  of  appropriate  antibiotics  has  become  both  more
complicated  and  may  delay  appropriate  therapy.16,17 This
study  analyzed  185  cases  of  infantile  CA  UTI,  and  showed  an
increasing  trend  in  the  occurrence  of  CA-ESBL  UTI.  Signiﬁ-
cant  differences  were  observed  in  defervescence  time  and
cortical  defect  on  DMSA  scans  in  CA-ESBL  UTI.  In  the  CA-ESBL
UTI  cases,  urinary  tract  abnormalities,  including  VUR,  were
more  frequent,  and  the  rates  of  resistance  to  non--lactam
antibiotics  were  relatively  high.  Urinary  tract  abnormalities
and  UTI  history  were  found  to  be  independent  risk  factors.
Over  the  past  two  decades,  there  has  been  wide  use
of  extended  broad-spectrum  antibiotics  to  counter  the
increasing  rates  of  ESBL-producing  bacteria  in  patients  with
7,18UTI  worldwide. E.  coli  and  Klebsiella  spp.,  the  most
common  UTI  pathogens,  have  various  antibiotic  resistance
mechanisms,  including  enhanced  drug  efﬂux,  alterations
of  the  drug  target,  and  production  of  plasmid-mediated
Table  3  Logistic  regression  of  risk  factors  associated  with
CA-ESBL  UTI  in  infants.
Risk  factors  Odds  ratio  (95%  CI)  p
Age  0.866  (0.733--1.025)  0.094
Renal abnormalities 2.741  (1.137--6.606) 0.025
Recent  hospitalization  1.964  (0.390--9.894)  0.413
Previous  UTI  10,295  (1404--75,492)  0.0
ESBL, extended-spectrum -lactamase; UTI, urinary tract infec-
tion.
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-lactamases.19 Resistance  is  usually  due  to  -lactamase
nzymes  called  ESBLs.  The  patterns  of  antibiotic  resistance
iffer  temporally  and  regionally.18,20,21 The  rates  of  ESBL-
roducing  E.  coli  range  from  2.2%  in  a  2011  Swiss  study18
o  55.0%  in  a  2009  Chinese  study.20 Several  factors  are
nvolved  in  the  rapid  spread  of  ESBL-producing  bacteria
n  countries  with  low  use  of  antibiotics,  including  acquisi-
ion  from  food,22 person-to-person  transmission  from  fecal
arriers,23 dissemination  of  ESBL-producing  bacteria  in  the
nvironment,24 and  the  existence  of  reservoirs,  such  as  long-
erm  care  centers.25
Most  studies  have  determined  that  the  risks  factors
or  CA-ESBL-producing  bacterial  infections  generally  are
ecent  hospitalization,  previous  UTI  episodes,  urinary  tract
bnormalities,  underlying  disease,  UTI  with  Klebsiella  spp.,
nd  use  of  cephalosporin  UTI  antimicrobial  prophylaxis.7--9
he  use  of  antimicrobial  prophylaxis  is  an  important  risk
actor  to  increase  antibiotic  resistance;  TMP-SMX  mini-
ally  decreased  antimicrobial  susceptibilities  compared  to
ephalosporin.26 As  only  two  patients  in  this  study  received
he  antimicrobial  prophylaxis,  it  was  not  possible  assess  the
isk  of  antimicrobial  prophylaxis.  In  the  present  study,  uri-
ary  tract  abnormalities  and  UTI  history  were  found  to  be
ndependent  risk  factors  for  future  CA-ESBL  UTI  in  infants.
owever,  a  high  number  of  CA-ESBL-producing  bacterial
nfections  occur  in  patients  without  obvious  risk  factors.27
n  fact,  in  the  present  study,  approximately  60%  of  patients
ith  CA-ESBL  UTI  had  no  risk  factors.  This  result  might  be
elated  to  the  constant  increase  in  the  number  of  healthy
arriers  colonized  with  ESBL-producing  bacteria.23
A  major  concern  regarding  ESBL-producing  bacteria  is
he  high  rate  of  cross-resistance  to  non--lactam  antibiotics
uch  as  ciproﬂoxacin,  aminoglycosides,  nitrofurantoin,  and
MP-SMX.  In  this  study,  61%  of  patients  showed  antibiotic
esistance  to  at  least  two  suitable  non--lactam  antibiotics
sed  to  treat  UTI.  Similar  results  have  been  reported  by
ther  investigators.28 The  increasing  incidence  of  multi-drug
esistance  by  ESBL-producing  bacteria  could  become  a  prob-
em  for  the  treatment  of  UTI.
Many  studies  have  reported  that  infection  by  these  bacte-
ia  might  lead  to  a  delay  in  appropriate  therapy  and  a
oncomitant  increase  in  the  rates  of  treatment  failure  and
omorbidity.21,29 Proposing  an  appropriate  empirical  antibi-
tic  treatment  for  CA-ESBL  UTI  is  difﬁcult,  and  initial
mpirical  antibiotic  therapy  is  often  unsuccessful.  Addition-
lly,  when  ESBL-producing  bacteria  are  isolated,  there  are
lmost  no  options  for  oral  therapy  to  improve  patient  symp-
oms.  In  the  present  study,  treatment  failure  was  more
requent  in  the  CA-ESBL  UTI  group;  however,  there  was
o  signiﬁcant  inter-group  difference  in  clinical  manifesta-
ions  such  as  bacteremic  UTI  or  renal  scarring.  Resistant
trains  were  not  associated  with  worsening  of  renal  out-
ome  in  the  present  study,  but  previous  studies  indicated
hat  ESBL-producing  bacterial  infection  increase  the  rates
f  treatment  failure  and  death.21,27,29
Several  studies  have  shown  increasing  recognition  of
SBL-producing  bacteria  as  a  cause  of  CA  infection.  Most
ata  on  CA-ESBL  infections  are  based  on  adult  popula-
ions,  and  relatively  few  pediatric  studies  are  available.8,9,30mong  them,  infantile  data  on  clinical  characteristics  of
A-ESBL  UTI  and  possible  risk  factors  are  scarce.  However,
s  the  incidence  of  ESBL-producing  bacteria  in  infants  with
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TIs  is  increasing,  it  is  important  to  understand  the  relevant
pidemiological  changes  in  infants.
This  study  has  some  limitations.  First,  this  was  retro-
pective  study;  therefore,  some  data  were  missing  from  the
edical  records.  Second,  this  study  entailed  a  single-center
nalysis  with  a  restricted  number  of  patients.  The  sample
ize  of  the  CA-ESBL  UTI  group  was  small,  thus  imposing  lim-
tations  on  statistical  power.  Third,  VCUG  was  performed
nly  when  image  study  ﬁndings  were  abnormal.  In  order  to
chieve  a  better  understanding  of  the  clinical  characteristics
nd  determine  the  risk  factors  for  UTIs  caused  by  ESBL-
roducing  bacteria  in  infants,  additional,  cohort  prospective
tudies  based  on  a  large  population  are  required.
In  conclusion,  the  incidence  of  UTI  caused  by  ESBL-
roducing  bacteria  has  increased  gradually  in  Korean
nfants.  Urinary  tract  abnormalities  and  previous  UTI  infec-
ion  were  found  to  be  signiﬁcant  independent  risk  factors
ssociated  with  CA-EBSL  UTI.  For  such  patients,  recognition
f  the  risk  factors  for  ESLB-producing  UTI  may  help  to  deter-
ine  appropriate  guidelines  for  its  management  and  more
ttention  to  the  choice  of  empirical  antibiotic  therapy  is
eeded.
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